![]() |
Quote:
Cherie |
Quote:
I am sure that there won't be any stones left unturned by any investigative body regarding these two cases. Considering the fact that these are the first two MS cases of PML on monotherapy, I am sure that everyone will be on high alert. |
Sally, this link has the amount of people using Tysabri. However, I am not sure if the number is correct. It seems numbers vary depending on what news report your reading.
http://www.bloomberg.com/apps/news?p...kFY&refer=home More than 31,800 multiple sclerosis patients use Tysabri, Biogen spokeswoman Naomi Aoki said. About 14,000 patients have taken Tysabri for more than a year, and 6,500 patients have taken it for 18 months or longer. |
Quote:
Thanks! Now it seems to be working. |
I wonder if this is what HarryZ was referring to awhile back. I would be interested in what he has to say.
Harry are you out there? |
This is now on the Patient Information Warning Label for Tysabri.
http://www.tysabri.com/tysbProject/t...q.xml#casespml Quote:
|
Additional information:
One of the patients, the one who is hospitalized and has been on Ty for 14 months, has a history of prior disease modifying therapies including azathioprine and beta-interferons. both patients are still alive and one has had a plasma exchange which is what the protocol is for PML. The EU does have a modified TOUCH protocol. |
Quote:
|
Quote:
http://www.sec.gov/Archives/edgar/da...14958ke8vk.htm As for the TOUCH protocol, I've been involved with the FDA and RISK Management panels. I went back through my notes from the last conference. |
I went to a seminar about two years ago. Of course, Tysabri risks were brought up. The neuro said they didn't expect to hear anything for 2 years or so. It was then, he said, that they expected more deaths.
I hope this is not the start of it. |
All times are GMT -5. The time now is 06:32 AM. |
Powered by vBulletin Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise (Lite) -
vBulletin Mods & Addons Copyright © 2025 DragonByte Technologies Ltd.